- Home
- IPHA vs FLL Comparison
IPHA vs FLL Comparison
Compare IPHA & FLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- FLL
- Stock Information
- Founded
- IPHA 1999
- FLL 1987
- Country
- IPHA France
- FLL United States
- Employees
- IPHA N/A
- FLL N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- FLL Hotels/Resorts
- Sector
- IPHA Health Care
- FLL Consumer Discretionary
- Exchange
- IPHA Nasdaq
- FLL Nasdaq
- Market Cap
- IPHA 160.1M
- FLL 165.2M
- IPO Year
- IPHA 2019
- FLL 1993
- Fundamental
- Price
- IPHA $2.24
- FLL $5.33
- Analyst Decision
- IPHA Strong Buy
- FLL Strong Buy
- Analyst Count
- IPHA 1
- FLL 4
- Target Price
- IPHA $11.50
- FLL $6.50
- AVG Volume (30 Days)
- IPHA 650.0K
- FLL 156.7K
- Earning Date
- IPHA 03-20-2025
- FLL 03-06-2025
- Dividend Yield
- IPHA N/A
- FLL N/A
- EPS Growth
- IPHA N/A
- FLL N/A
- EPS
- IPHA N/A
- FLL N/A
- Revenue
- IPHA $36,202,722.00
- FLL $279,132,000.00
- Revenue This Year
- IPHA N/A
- FLL $23.82
- Revenue Next Year
- IPHA $93.37
- FLL $11.07
- P/E Ratio
- IPHA N/A
- FLL N/A
- Revenue Growth
- IPHA N/A
- FLL 28.57
- 52 Week Low
- IPHA $1.29
- FLL $3.77
- 52 Week High
- IPHA $3.51
- FLL $5.94
- Technical
- Relative Strength Index (RSI)
- IPHA 63.01
- FLL 60.18
- Support Level
- IPHA $2.07
- FLL $5.10
- Resistance Level
- IPHA $2.38
- FLL $5.56
- Average True Range (ATR)
- IPHA 0.13
- FLL 0.19
- MACD
- IPHA 0.04
- FLL -0.02
- Stochastic Oscillator
- IPHA 78.79
- FLL 58.18
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About FLL Full House Resorts Inc.
Full House Resorts Inc owns, operates, develops, manages, and invests in casinos and related hospitality and entertainment facilities. It offers facilities related to gaming, hotel, dining, entertainment, retail, and other amenities. The group's reportable segments are Midwest & South, West, and Contracted Sports Wagering, It generates the majority of its revenue from the Midwest & South segment which includes Silver Slipper Casino and Hotel, Rising Star Casino Resort, and American Place. The west segment includes Grand Lodge, Stockman's Casino, Bronco Billy's Casino and Hotel, and Chamonix Casino Hotel. The Contracted Sports Wagering segment comprises on-site and online sports wagering skins.